Related Experiment Videos
Intercellular adhesion molecule 1 on liver allografts during rejection
D H Adams1, S G Hubscher, J Shaw
1Liver Unit, Queen Elizabeth Hospital, Birmingham.
Lancet (London, England)
|November 11, 1989
Summary
Intercellular adhesion molecule 1 (ICAM-1) expression increases in liver transplant rejection. Reducing ICAM-1 with corticosteroids may be key to successful treatment, aiding graft survival.
Area of Science:
- Immunology
- Transplantation Medicine
- Cellular Biology
Background:
- Intercellular adhesion molecule 1 (ICAM-1) is a key mediator in immune responses.
- ICAM-1 interacts with lymphocyte-function-associated antigen 1 (LFA-1) on leukocytes.
- Understanding ICAM-1's role in liver transplant rejection is crucial for improving outcomes.
Purpose of the Study:
- To investigate ICAM-1 expression levels in liver allografts.
- To correlate ICAM-1 expression with different stages of liver transplant rejection.
- To evaluate the effect of corticosteroid treatment on ICAM-1 expression.
Main Methods:
- Immunohistochemical analysis of liver biopsy samples.
- Quantification of ICAM-1 expression on bile ducts, endothelium, and hepatocytes.
- Comparison of ICAM-1 levels in patients with acute rejection, chronic rejection, resolving rejection, stable grafts, and non-rejection complications.
Main Results:
- Elevated ICAM-1 expression was observed in acute and chronic liver transplant rejection.
- Progressive rejection correlated with increased ICAM-1 on bile ducts and hepatocytes.
- High-dose corticosteroid treatment significantly reduced ICAM-1 expression in resolving rejection.
Conclusions:
- ICAM-1 induction is implicated in the inflammatory response during liver transplant rejection.
- Targeting ICAM-1 may be a critical mechanism for corticosteroid therapy in managing rejection.
- ICAM-1 expression levels can serve as a biomarker for rejection severity and treatment response.